The Food and Drug Administration today issued a request for public comment on a series of questions regarding current approaches to evaluating artificial intelligence-enabled medical device performance in real-world applications. This includes approaches to detect, assess and mitigate performance changes over time to help assure the devices remain safe and effective throughout their life cycle. The FDA is accepting comments at www.regulations.gov until Dec. 1. The notice follows a request by the Office of Science and Technology Policy issued Sept. 26 that seeks feedback on federal regulations that hinder AI development, deployment or adoption.

Headline
The AHA Nov. 3 launched a new webpage, Artificial Intelligence Policy and Advocacy, featuring AHA policy letters, statements, fact sheets, news and other…
Headline
The West Health Accelerator at the AHA’s Health Research & Educational Trust will host a virtual session Oct. 29 at 2:30 p.m. ET on how hospitals are…
Headline
The AHA provided recommendations to the Food and Drug Administration Oct. 19 on potential regulatory frameworks for generative artificial intelligence-enabled…
Headline
The Agency for Healthcare Research and Quality Oct. 7 announced the launch of the Super Intelligence for Healthcare Improvement Initiative, a two-part…
Headline
An AHA blog published Oct. 5 responds to a Blue Cross Blue Shield Association report suggesting that hospitals’ use of artificial intelligence-enabled…
Headline
The AHA provided comments Sept. 30 to the Senate Homeland Security and Governmental Affairs Subcommittee on Disaster Management, District of Columbia and…